Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20

Latest Articles in Serum Institute of India SII

Govt Expert Panel Recommends Regular Market Approval For Covishield, Covaxin

Pharma companies Serum Institute of India (SII) and Bharat Biotech had submitted applications to the Drugs Controller General of India (DCGI) seeking regular market authorisation for their respective COVID-19 vaccines Covishield and Covaxin.

Read More

Serum Institute Urges Govt To Fast-Track Movement Of Its COVID-19 Vaccine Covishield

The Serum Institute will commence its Covid vaccine export under the COVAX programme from November 23 and Nepal will receive the first lot of Covishiled on November 24.

Read More

AstraZeneca Set For 'Modest' Profit From Covid-19 Vaccine

The company is now expecting to progressively transition the vaccine to modest profitability as new orders are received, notes the AstraZeneca's latest financial results update.

Read More

Novavax Files For Emergency Use Listing Of COVID-19 Vaccine With WHO

Novavax will make further submissions to enable vaccine supply from additional manufacturing sites in Novavax's global supply chain.

Read More

Centre Got Over 65.25 Crore Covishield Doses, 9.1 Crore Covaxin Jabs Till September 19

The SII has informed the government that it will be able to supply around 22 crore doses of Covishield in October.

Read More

Biocon Biologics To Offer 15% Stake To Serum Institute Life Sciences At Valuation Of $4.9 Billion

Biocon Biologics will also establish, at its cost, a vaccine R&D division to support the strategic alliance in developing both vaccines and biologics for communicable diseases.

Read More

DGCI Gives Nod For Phase 2/3 Trials Of Biological E's COVID-19 Vaccine On Kids Aged Between 5 & 18

India's drug regulator in July granted permission to Serum Institute of India (SII) for conducting phase 2/3 trials of Covovax on children aged 2 to 17 years with certain conditions.

Read More

Serum Institute Writes To Union Health Minister Proposing Reforms In Drug Regulatory System

The letter stated that on the directions of the prime minister, a high-powered Inter-Ministerial Committee for reforming the drug regulatory systems in India was formed under the chairmanship of then OSD, Rajesh Bhushan who is presently the health secretary.

Read More

Serum Institute Asks Govt To Take Up Inclusion Of Covishield In Vaccination Passport With EU

The letter also mentions that AstraZeneca-SII Covishield has been manufactured under technology transfer from Oxford/AstraZeneca and that clinical trials of the vaccine have been conducted successfully abroad and has been approved by MHRA for emergency use approval.

Read More

India Likely To Waive Customs Duty On COVID-19 Vaccine Imports

The government presently levies 10 per cent customs or import duty plus a 16.5 per cent I-GST and social welfare surcharge on vaccines coming from overseas

Read More

Covovax Trials Begin In India, Hope To Launch It By Sept 2021: Adar Poonawalla

American vaccine company Novavax, Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in low and middle-income countries and India.

Read More

Will Try To Supply More Doses Of COVID-19 Vaccine To UK Later: Serum Institute

The UK's National Health Service has warned of a significant reduction in weekly supplies of vaccines to protect against COVID-19 by the end of this month.

Read More

UK To Receive 10 Million Astrazeneca COVID-19 Vaccine Doses From India's Serum Institute

The UK government said the agreement follows assurances from the SII that providing doses to the UK would not impact its commitment to provide vaccines to poorer countries

Read More

UK Delegation Visits Serum Institute

'We discussed how to further enhance the existing relationship between India and the UK on manufacturing and innovation in the healthcare space.'

Read More

Serum Institute Of India Delays Vaccines For Private Sale In Bangladesh; Focus On State Campaigns

Beximco's chief operating officer told Reuters last month the company could buy up to 3 million doses of the vaccine from SII at about $8 each for sale on the private market.

Read More